153 related articles for article (PubMed ID: 36974810)
1. Effect of Interstitial Lung Abnormality on Concurrent Chemoradiotherapy-treated Stage III Non-small Cell Lung Cancer Patients.
Jeong WG; Kim YH; Ahn SJ; Jeong JU; Lee BC; Cho IJ; Kim YH
Anticancer Res; 2023 Apr; 43(4):1797-1807. PubMed ID: 36974810
[TBL] [Abstract][Full Text] [Related]
2. Subpleural fibrotic interstitial lung abnormalities are implicated in non-small cell lung cancer radiotherapy outcomes.
Ito M; Katano T; Okada H; Sakuragi A; Minami Y; Abe S; Adachi S; Oshima Y; Ohashi W; Kubo A; Fukui T; Ito S; Suzuki K
Radiol Oncol; 2023 Jun; 57(2):229-238. PubMed ID: 37078697
[TBL] [Abstract][Full Text] [Related]
3. Chemoradiotherapy for locally advanced lung cancer patients with interstitial lung abnormalities.
Higo H; Kubo T; Makimoto S; Makimoto G; Ihara H; Masaoka Y; Ninomiya T; Ichihara E; Ohashi K; Sato A; Hotta K; Tabata M; Takigawa N; Maeda Y; Kiura K
Jpn J Clin Oncol; 2019 May; 49(5):458-464. PubMed ID: 30793176
[TBL] [Abstract][Full Text] [Related]
4. Clinical features and risk factors for interstitial lung disease spreading in low-dose irradiated areas after definitive radiotherapy with or without durvalumab consolidation therapy for patients with non-small cell lung cancer.
Sakagami M; Inokuchi H; Mukumoto N; Itoyama H; Hamaura N; Yamagishi M; Mukumoto N; Matsuda S; Kabata D; Shibuya K
Radiat Oncol; 2023 May; 18(1):87. PubMed ID: 37217919
[TBL] [Abstract][Full Text] [Related]
5. Incidence and Risk Factors of Symptomatic Radiation Pneumonitis in Non-Small-Cell Lung Cancer Patients Treated with Concurrent Chemoradiotherapy and Consolidation Durvalumab.
Shintani T; Kishi N; Matsuo Y; Ogura M; Mitsuyoshi T; Araki N; Fujii K; Okumura S; Nakamatsu K; Kishi T; Atsuta T; Sakamoto T; Narabayashi M; Ishida Y; Sakamoto M; Fujishiro S; Katagiri T; Kim YH; Mizowaki T
Clin Lung Cancer; 2021 Sep; 22(5):401-410. PubMed ID: 33678582
[TBL] [Abstract][Full Text] [Related]
6. Neutrophil-lymphocyte ratio and a dosimetric factor for predicting symptomatic radiation pneumonitis in non-small-cell lung cancer patients treated with concurrent chemoradiotherapy.
Lee YH; Choi HS; Jeong H; Kang KM; Song JH; Lee WS; Lee GW; Song HN; Kim HG; Kang MH; Rhee DY; Jeong BK
Clin Respir J; 2018 Mar; 12(3):1264-1273. PubMed ID: 28618180
[TBL] [Abstract][Full Text] [Related]
7. Predicting factors of symptomatic radiation pneumonitis induced by durvalumab following concurrent chemoradiotherapy in locally advanced non-small cell lung cancer.
Mayahara H; Uehara K; Harada A; Kitatani K; Yabuuchi T; Miyazaki S; Ishihara T; Kawaguchi H; Kubota H; Okada H; Ninomaru T; Shindo C; Hata A
Radiat Oncol; 2022 Jan; 17(1):7. PubMed ID: 35033139
[TBL] [Abstract][Full Text] [Related]
8. Prospective multicenter cohort study of durvalumab for patients with unresectable stage III non-small cell lung cancer and grade 1 radiation pneumonitis.
Sugimoto T; Fujimoto D; Sato Y; Tamiya M; Yokoi T; Taniguchi Y; Hino A; Hata A; Uchida J; Fukuda Y; Hara S; Kanazu M; Matsumoto H; Kokubo M; Yamamoto N
Lung Cancer; 2022 Sep; 171():3-8. PubMed ID: 35863254
[TBL] [Abstract][Full Text] [Related]
9. Radiation pneumonitis after definitive concurrent chemoradiotherapy with cisplatin/docetaxel for non-small cell lung cancer: Analysis of dose-volume parameters.
Katsui K; Ogata T; Watanabe K; Katayama N; Kuroda M; Kiura K; Hiraki T; Maeda Y; Toyooka S; Kanazawa S
Cancer Med; 2020 Jul; 9(13):4540-4549. PubMed ID: 32364685
[TBL] [Abstract][Full Text] [Related]
10. Durvalumab for patients with unresectable stage III non-small cell lung cancer and grade 1 radiation pneumonitis following concurrent chemoradiotherapy: a multicenter prospective cohort study.
Sugimoto T; Fujimoto D; Sato Y; Tamiya M; Yokoi T; Tamiya A; Iwasawa S; Hata A; Uchida J; Fukuda Y; Hara S; Kanazu M; Hirano K; Kokubo M; Yamamoto N
Invest New Drugs; 2021 Jun; 39(3):853-859. PubMed ID: 33405089
[TBL] [Abstract][Full Text] [Related]
11. Endostar acts as a pneumonitis protectant in patients with locally advanced non-small cell lung cancer receiving concurrent chemoradiotherapy.
Chen K; Li S; Chen M; Jin Z; Sun X; Zhou S; Yang H
BMC Cancer; 2024 Feb; 24(1):257. PubMed ID: 38395838
[TBL] [Abstract][Full Text] [Related]
12. Dose-volume parameters predict radiation pneumonitis after induction chemoradiotherapy followed by surgery for non-small cell lung cancer: a retrospective analysis.
Katsui K; Ogata T; Watanabe K; Katayama N; Soh J; Kuroda M; Kiura K; Maeda Y; Toyooka S; Kanazawa S
BMC Cancer; 2019 Nov; 19(1):1144. PubMed ID: 31771538
[TBL] [Abstract][Full Text] [Related]
13. Radiation pneumonitis in patients with non-small-cell lung cancer receiving chemoradiotherapy and an immune checkpoint inhibitor: a retrospective study.
Jang JY; Kim SS; Song SY; Kim YJ; Kim SW; Choi EK
Radiat Oncol; 2021 Dec; 16(1):231. PubMed ID: 34863244
[TBL] [Abstract][Full Text] [Related]
14. Acute severe radiation pneumonitis among non-small cell lung cancer (NSCLC) patients with moderate pulmonary dysfunction receiving definitive concurrent chemoradiotherapy: Impact of pre-treatment pulmonary function parameters.
Zhou Y; Yan T; Zhou X; Cao P; Luo C; Zhou L; Xu Y; Liu Y; Xue J; Wang J; Wang Y; Lu Y; Liang B; Gong Y
Strahlenther Onkol; 2020 Jun; 196(6):505-514. PubMed ID: 31828393
[TBL] [Abstract][Full Text] [Related]
15. Radiation pneumonitis in lung cancer patients treated with chemoradiation plus durvalumab.
Shaverdian N; Thor M; Shepherd AF; Offin MD; Jackson A; Wu AJ; Gelblum DY; Yorke ED; Simone CB; Chaft JE; Hellmann MD; Gomez DR; Rimner A; Deasy JO
Cancer Med; 2020 Jul; 9(13):4622-4631. PubMed ID: 32372571
[TBL] [Abstract][Full Text] [Related]
16. Interstitial lung abnormalities in patients with stage I non-small cell lung cancer are associated with shorter overall survival: the Boston lung cancer study.
Hida T; Hata A; Lu J; Valtchinov VI; Hino T; Nishino M; Honda H; Tomiyama N; Christiani DC; Hatabu H
Cancer Imaging; 2021 Jan; 21(1):14. PubMed ID: 33468255
[TBL] [Abstract][Full Text] [Related]
17. Quantification of diffuse parenchymal lung disease in non-small cell lung cancer patients with definitive concurrent chemoradiation therapy for predicting radiation pneumonitis.
An YC; Kim JH; Noh JM; Yang KM; Oh YJ; Park SG; Pyo HR; Lee HY
Thorac Cancer; 2023 Dec; 14(36):3530-3539. PubMed ID: 37953066
[TBL] [Abstract][Full Text] [Related]
18. Symptomatic Radiation Pneumonitis in NSCLC Patients Receiving EGFR-TKIs and Concurrent Once-daily Thoracic Radiotherapy: Predicting the Value of Clinical and Dose-volume Histogram Parameters.
Yang X; Mei T; Yu M; Gong Y
Zhongguo Fei Ai Za Zhi; 2022 Jun; 25(6):409-419. PubMed ID: 35747920
[TBL] [Abstract][Full Text] [Related]
19. Chemoradiation-induced pneumonitis in patients with unresectable stage III non-small cell lung cancer: A systematic literature review and meta-analysis.
Kuang Y; Pierce CM; Chang HC; Sosinsky AZ; Deitz AC; Keller SM; Samkari A; Uyei J
Lung Cancer; 2022 Dec; 174():174-185. PubMed ID: 35717343
[TBL] [Abstract][Full Text] [Related]
20. The safety and efficacy of durvalumab consolidation therapy in the management of patients with stage III non-small-cell lung cancer and preexisting interstitial lung disease.
Kawanaka Y; Yasuda Y; Tanizaki J; Iwashima D; Nonagase Y; Uemasu K; Hirayama Y; Ogura M; Ozaki T; Takahashi KI
Respir Investig; 2022 Sep; 60(5):667-673. PubMed ID: 35725721
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
